Selexis SA to Present at Cell Line Development and Engineering 2013

Share Article

Selexis’ co-founder and scientific advisory board member will present on approaches of CHO cell engineering and clone characterization for improved protein expression

Selexis Co-founder, Prof. Nicolas Mermod, Ph.D.

Nicolas Mermod, PhD

Nicolas Mermod, Ph.D., will present “Omics-based approaches of CHO cell engineering and clone characterisation for improved protein expression”

Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that the Company’s co-founder will present data on the Company’s core technology at the Cell Line Development and Engineering 2013 conference being held February 11 – 15 in Vienna, Austria. Selexis’ co-founder and scientific advisory board member, Nicolas Mermod, PhD, Professor of Biotechnology at Faculty of Biology and Medicine of the University of Lausanne, will present, “Omics-based approaches of CHO cell engineering and clone characterisation for improved protein expression,” on Friday, February 15 at 1:45 PM as part of the CHO Cell Engineering tract.

Presentation Abstract
“Omics-based approaches of CHO cell engineering and clone characterisation for improved protein expression”
Incorporation of epigenetic regulatory DNA elements to prevent silencing can yield high and stable expression from CHO cells with a high frequency. We determined the sequence of a CHO genome used for pharmaceutical production and of derived therapeutic producing clones and allowed the characterisation of the alterations of the genomic and transgene sequence of candidate cell lines. This presentation will illustrate how a systematic and multi-level ‘Omics’ approach may be used to improve the expression of pharmaceutical proteins.

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and morestable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Robert Meister
Selexis SA
(602) 953-1716
Email >

Robert Meister
Follow us on
Visit website